Camber Launches Olmesartan Medoxomil Tablets, USP

Piscataway, NJ, June 3, 2025 –Camber Pharmaceuticals is excited to announce the addition of Olmesartan Medoxomil Tablets, USP to its current portfolio.
Olmesartan Medoxomil Tablets, USP are indicated for the treatment of hypertension in adults and children six years of age and older, to lower blood pressure.
Olmesartan Medoxomil Tablets, USP are available in 5 mg, 20 mg and 40 mg strengths, packaged in bottles of 30 and 90 tablets.
To find out more information on Olmesartan Medoxomil Tablets, USP, please visit: www.camberpharma.com/olmesartan
Recent articles
- Camber’s Parent Company, Hetero, Partners with the Gates Foundation to Supply Generic Lenacapavir for HIV Prevention
- Camber Adds 800 mg Darunavir Tablets to Product Family
- Camber Expands Portfolio with 10 New Generic Drug Launches in Q3 2025
- Camber Launches Indomethacin Suppositories
- Camber Launches Voriconazole for Injection
- Camber Launches Magnesium Sulfate Injection